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P E R S P E C T I V E
Short- and long- term evolution in our arms race with cancer: 












cells	operates	only	over	 the	 short	 term	and	 is	discontinuous	—	all	
resistance	adaptations	are	lost	each	time	a	cancer	patient	dies.	Thus,	





The	 last	 two	 decades	 have	 seen	 a	 remarkable	 acceleration	 in	 the	
introduction	 of	 new	 drugs	 and	 other	 innovative	 therapies	 for	 the	





of	 a	 patient’s	 own	T	 cells	 (Klebanoff,	 Rosenberg,	&	Restifo,	 2016;	
Lopez	&	Banerji,	2017;	Pardoll,	2012).	The	excitement	surrounding	
these	advances	is,	however,	universally	tempered	by	the	recognition	
that	 cancer	 cells	 have	 demonstrated	 a	 powerful	 ability	 to	 evolve	
resistance	against	virtually	all	classes	of	therapies	other	than	com-
plete	surgical	excision	(Faltas	et	al.,	2016;	Gottesman,	Lavi,	Hall,	&	
Gillet,	 2016).	 After	 the	 dramatic	 initial	 successes	 of	 targeted	 che-
motherapies	for	treatment	of	chronic	myeloid	leukemia,	failures	of	
later-	introduced	drugs	have	been	profoundly	disappointing	(Gillies,	
Verduzco,	 &	 Gatenby,	 2012;	 Horne	 et	al.,	 2012;	 Schmitt,	 Loeb,	 &	
Salk,	2016).	Just	as	had	been	observed	with	the	less	selective	cyto-
toxic	chemotherapeutic	drugs	(Chabner	&	Roberts,	2005),	resistance	
has	 been	 shown	 to	 evolve	 through	 many	 mechanisms,	 including	
mutational	changes	in	the	target,	downstream	activation	of	inhibited	
pathways,	substitution	of	alternate	pathways	for	growth	activation,	










the	 timescales	 of	 the	 evolutionary	 processes	 involved,	 including	
the	oncogenic	 (“intrasomatic”)	 selection	 in	cancer	cells	on	 the	one	
hand,	versus	the	process	of	cultural	evolution	in	human	populations,	
through	 which	 scientific	 and	 technological	 knowledge	 is	 accumu-
lated	over	time	(Mesoudi	et	al.,	2013),	on	the	other	hand.	My	thesis	
is	that	our	ability	to	build	an	ever-	expanding	set	of	anticancer	tactics	







2  | ARMS R ACES BET WEEN HUMAN 
POPUL ATIONS AND INJURIOUS 
ORGANISMS
To	frame	this	argument,	it	is	helpful	to	begin	with	more	typical	evo-
lutionary	 arms	 races	 that	 occur	 between	 human	 populations	 and	
various	 injurious	 organisms	 whose	 populations	 we	 perennially	 at-




and	organisms	 that	attack	or	 infest	our	homes.	To	 suppress	 these	
disease	or	pest	populations,	we	deploy	a	huge	array	of	drugs,	pes-
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Consortium	2012).	 In	 each	 case,	 this	 sets	 in	motion	 an	 evolution-
ary	 arms	 race,	 pitting	 one	 long-	term	evolutionary	 process	 (human	
cultural	evolution,	as	we	invent	new	control	tactics)	against	another	
long-	term	evolutionary	process	 (evolution	of	 resistance	by	natural	










insect	 vectors	 of	 disease,	 show	 that	 the	 outcomes	 of	 these	 bal-
anced	evolutionary	processes	are	uncertain	(Arts	&	Hazuda,	2012;	





In	 attempting	 to	 control	 populations	 of	 injurious	 organisms,	










3  | ARMS R ACES BET WEEN HUMAN 
POPUL ATIONS AND C ANCEROUS CELL 
LINES
We	also	 find	 ourselves	 battling	 another	 unwanted	 replicator:	Our	






In	 the	 short	 term,	 cancerous	 cell	 lines	have	an	outsized	ability	
to	 evolve	 resistance	 to	 chemotherapies	 (Greaves	 &	Maley,	 2012;	






2015).	On	 top	of	 this,	 some	 cancer	 cells	 exhibit	 an	 insidious	 form	
of	positive	 feedback	 that	 leads	 to	 an	 acceleration	of	 their	 genetic	
and	epigenetic	instability:	As	cancer	cells	acquire	mutations,	genes	






fusion–bridge	 cycles,	 nucleoside	 imbalances,	 and	DNA	 replication	






evolutionary	 potential	 over	 the	 short	 term,	 such	 that	 cancer	 cells	
become	 so	 heterogeneous	 and	malleable	 that	mutants	 conferring	
resistance	 to	 virtually	 any	 therapy	 often	 exist	 before	 the	 therapy	
is	initiated	(Faltas	et	al.,	2016;	Greaves	&	Maley,	2012;	Loeb,	2011;	














Summers,	 2005;	 Ewald	 &	 Swain	 Ewald,	 2012;	 Haig,	 2015	 Merlo,	















Despite	 the	 decidedly	 mixed	 record	 of	 success	 for	 newly	 in-
troduced	 cancer	 drugs,	 we	 are	 now	 beginning	 to	 see	 how	 this	
asymmetry	 in	our	 arms	 race	 against	 cancer—a	 continuous	process	
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of	cultural	evolution	pitted	against	a	discontinuous	process	of	on-
cogenic	 selection—can	give	us	 a	 decisive	 advantage	over	 the	 long	
haul.	Governmental	and,	 increasingly,	private-	sector	 investment	 in	





























concern	 (Goldberg	 et	al.,	 2012;	Zur	Wiesch,	Kouyos,	 Engelstädter,	
Regoes,	&	Bonhoeffer,	2011):	Drug	cocktails	have	provided	a	means	
of	 coping	 with	 drug-	resistant	 bacterial	 and	 viral	 pathogens	 (e.g.,	
Mycobacterium tuberculosis,	 Gandhi	 et	al.,	 2010;	H. pylori,	Hu,	 Zhu,	
&	Lu,	2017;	HIV,	Arts	&	Hazuda,	2012),	and	toxin	combinations	can	
effectively	 slow	 resistance	 evolution	 in	 insect	 herbivores	 feeding	
on	 transgenic	 crop	 plants	 (Carrière,	 Fabrick,	 &	 Tabashnik,	 2016).	








then	given	 the	huge	number	of	cells	present	 in	even	small	 tumors	
(frequently	>108;	Loeb,	2011),	we	expect	>103	cells	to	be	resistant,	
and	use	of	a	single	drug	is	bound	to	fail,	as	has	sadly	been	abundantly	
confirmed	 in	 practice.	 But	 combining	 two	 drugs	 raises	 the	 bar:	 If	
each	drug	can	kill	susceptible	tumor	cells	using	an	independent	mode	
of	 action,	 then	 only	 clones	 harboring	 two	mutations	 can	 survive,	








involved	 deploying	 multiple	 cytotoxic	 chemotherapies	 together	
(e.g.,	 methotrexate	+	vincristine	+	6-	mercaptopurine	+	prednisone,	
“POMP,”	 for	 childhood	 acute	 lymphoblastic	 leukemia;	 nitrogen	
mustard	+	vincristine	+	procarbazine	+	prednisone,	 “MOPP”,	 for	
Hodgkin’s	 lymphoma	 [Chabner	 &	 Roberts,	 2005],	 platinum	+	vin-
blastine	+	bleomycin,	 “PVB,”	 for	 testicular	 cancer	 [Einhorn,	 1981]).	
Combinatorial	 therapies	 can	 still	 fail	when	mutations	 emerge	 that	




of	 side	 effects	 (Lopez	&	Banerji,	 2017)	 and	potentially	 prohibitive	
costs.	But	combinatorial	therapies	built	with	increasingly	selective,	

















4  | INFEC TIOUS AND PATHOGEN- 







Swain	 Ewald,	 2012).	 Pathogens	 are	 more	 different	 biochemically	
from	healthy	human	cells	than	are	human	tumor	cells,	offering	greater	
opportunities	 for	 selective	 toxicity	 (Ewald	 &	 Swain	 Ewald,	 2014,	
2015),	 as	well	 as	more	abundant	preventive	approaches	 to	cancer	
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(e.g.,	 vaccination).	 Capitalizing	 on	 these	 opportunities,	 advances	
in	 the	 treatment	 some	pathogen-	associated	cancers	are	beginning	
to	 reduce	 cancer	 incidence	 and	 mortality	 (Casper	 &	 Fitzmaurice,	
2016;	Ewald	&	Swain	Ewald,	2014;	Global	Burden	of	Disease	Cancer	
Collaboration	2017;	Plummer	et	al.,	2016).	But,	might	the	evolution-
ary	 continuity	 within	 pathogen	 populations	 cause	 our	 arms	 race	
with	 these	cancers	 to	unfold	 in	a	qualitatively	different,	and	more	








cancer	 largely	 by	 eliciting	 chronic	 inflammation	 or	 immune	 sup-






increases	 in	 cancer	 risk	 (e.g.,	Schistosoma	 spp.,	HIV;	Ewald	&	Swain	
Ewald,	 2012,	 2013,	 2014,	 2015).	 The	 fitness	of	 these	pathogens	 is	
not	directly	enhanced	by	neoplasia	 in	 their	host.	 Instead,	 they	may	
benefit	 from	 the	 inflammation	 of	 host	 tissues,	which	may	 increase	
the	 availability	 of	 nutrients	 (e.g.,	Helicobacter pylori;	Graham,	 2015;	
D.	 Y.	 Graham,	 personal communication)	 or	 from	 the	 suppression	 of	











































































































controlled	 cell	 proliferation	 as	 a	 consequence	 (Chang,	 Moore,	 &	
Weiss,	2017).	Evolution	 in	 these	viral	populations	will,	 in	both	 the	
short	and	long	terms,	oppose	both	direct	antiviral	treatments	(e.g.,	
in	response	to	screen-	and-	treat	programs	against	hepatitis	B	and	C	
virus	 infections;	 Plummer	 et	al.,	 2016)	 and	 anticancer	 treatments.	
We	have,	however,	made	great	strides	 in	preventing	at	 least	some	
































2016;	Metzger	 &	Goff,	 2016)	 shows	 how	 fortunate	we	 are	 that	
we	 lack	any	 such	cell	 lines.	Our	highly	polymorphic	major	histo-
compatibility	 complex	 (MHC)	 loci	 are	 likely	 our	 primary	defense	
against	 the	 future	 emergence	 of	 such	 cancers	 (Ujvari,	 Gatenby	
et	al.,	2016;	Ujvari,	Papenfuss	et	al.,	2016).
Thus,	although	the	timescale	of	the	arms	race	between	human	
populations	 and	 pathogen-	associated	 cancers	 may	 be	 more	 sym-
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